Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Agennix Lung Cancer Drug in Doubt After Clinical Trial Failure

Aug. 6 (Bloomberg) -- Agennix AG’s experimental treatment for non-small cell lung cancer failed to meet targets in a late-stage trial, casting doubt on the German biotechnology company’s future.

Talactoferrin, a replica of the human protein lactoferrin, didn’t meet its primary endpoint of improving overall survival rate, Agennix said today in a statement.

“We are extremely disappointed and surprised with today’s results, especially considering the earlier promising results we had seen in two randomized Phase II trials with talactoferrin alfa in non-small cell lung cancer,” said Rajesh Malik, chief medical officer. “We plan to thoroughly analyze the data to better understand these results.”

Tests of the drug involved 720 patients worldwide whose cancer hadn’t responded to two previous therapies. The primary target of the trial was overall survival and the secondary goal was the drug’s effectiveness in delaying or halting the spread of the disease.

To contact the reporter on this story: Allison Connolly in Frankfurt at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.